Caring Ambassadors Hepatitis C Program Newsletter

March, 2010





Text Box: Clinical Trials, Cohort Studies, Pilot Studies


Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance.

Schulte B, Schütt S, Brack J, et al. Drug Alcohol Depend. 2010 Feb 16. [Epub ahead of print]


Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Bruno S, Shiffman ML, Roberts SK, et al. Hepatology. 2010 Feb;51(2):388-97.


Efficacy and tolerability of peginterferon alfa-2a or alfa-2b plus ribavirin in the daily routine treatment of patients with chronic hepatitis C in Germany: The PRACTICE Study.

Witthoeft T, Hueppe D, John C, et al. J Viral Hepat. 2010 Feb 11. [Epub ahead of print]


Clinical trial: low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3 - efficacy, tolerability, viral kinetics and cytokine response. Rotman Y, Borg BB, Soza A, et al. Aliment Pharmacol Ther. 2010 Feb 16. [Epub ahead of print]


Clinical trial: efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebo-controlled study in patients with chronic hepatitis C. Shiffman ML, Pockros P, McHutchison JG, et al. Aliment Pharmacol Ther. 2010 Feb 16. [Epub ahead of print]

 Schiff ER, Morris M, Burgess G.


Short versus standard treatment with Pegylated interferon alfa-2a plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the CLEO trial. Mecenate F, Pellicelli AM, Barbaro G, et al. BMC Gastroenterol. 2010 Feb 19;10(1):21. [Epub ahead of print]


Farglitazar lacks antifibrotic activity in patients with chronic hepatitis c infection.

McHutchison J, Goodman Z, Patel K, et al. Gastroenterology. 2010 Feb 12. [Epub ahead of print]


Replicated association between an il28b gene variant and a sustained response to pegylated interferon and ribavirin. McCarthy JJ, Li JH, Thompson A, et al. Gastroenterology. 2010 Feb 19. [Epub ahead of print]


Prognostic value of Ishak fibrosis stage: findings from the hepatitis C antiviral long-term treatment against cirrhosis trial. Everhart JE, Wright EC, Goodman ZD, et al. Hepatology. 2010 Feb;51(2):585-94.


Reduction of insulin resistance with effective clearance of hepatitis C infection: Results from the Halt-C Trial. Delgado-Borrego A, Jordan SH, Negre B, et al. Clin Gastroenterol Hepatol. 2010 Feb 12. [Epub ahead of print]


Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection. Satapathy SK, Lingisetty CS, Proper S, Chaudhari S, Williams S. J Clin Gastroenterol. 2010 Feb;44(2):140-5.


Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort. Morin T, Pariente A, Lahmek P, et al. Eur J Gastroenterol Hepatol. 2010 Feb;22(2):157-66.


Causes and predictive factors of mortality in a cohort of patients with hepatitis c virus-related cryoglobulinemic vasculitis treated with antiviral therapy. Landau DA, Scerra S, Sene D, et al. J Rheumatol. 2010 Jan 28. [Epub ahead of print]


Knowledge of hepatitis C virus screening in long-term pediatric cancer survivors: a report from the Childhood Cancer Survivor Study. Lansdale M, Castellino S, Marina N, et al. Cancer. 2010 Feb 15;116(4):974-82.


Mutations in the interferon sensitivity determining region and virological response to combination therapy with pegylated-interferon alpha 2b plus ribavirin in patients with chronic hepatitis C-1b infection. Nakagawa M, Sakamoto N, Ueyama M, et al. J Gastroenterol. 2010 Jan 30. [Epub ahead of print]


Complete blood count, measures of iron status and inflammatory markers in inner-city African Americans with undiagnosed hepatitis C seropositivity. Ufearo H, Kambal K, Onojobi GO, et al. Clin Chim Acta. 2010 Feb 1. [Epub ahead of print]


Text Box: Basic and Applied Science, Pre-Clinical Studies


Thermal stability and inactivation of hepatitis C virus grown in cell culture. Song H, Li J, Shi S, Yan L, Zhuang H, Li K. Virol J. 2010 Feb 18;7(1):40. [Epub ahead of print]


Human liver chimeric mice provide a model for hepatitis B and C virus infection and treatment. Bissig KD, Wieland SF, Tran P, et al. J Clin Invest. 2010 Feb 22. pii: 40094. doi: 10.1172/JCI40094. [Epub ahead of print]


Practical evaluation of a mouse with chimeric human liver model for hepatitis c virus infection using an NS3-4A protease inhibitor. Kamiya N, Iwao E, Hiraga N, et al. J Gen Virol. 2010 Feb 17. [Epub ahead of print]


Selection-driven immune escape is not a significant factor in the failure of CD4 T cell responses in persistent hepatitis C virus infection. Fuller MJ, Shoukry NH, Gushima T, et al. Hepatology. 2010 Feb;51(2):378-87.


Genetic diversity of NS5A protein from hepatitis C virus genotype 3a and its relationship to therapy response. Bittar C, Jardim AC, Yamasaki LH, et al. BMC Infect Dis. 2010 Feb 23;10(1):36. [Epub ahead of print]


Hepatitis C virus core protein enhances Telomerase activity in Huh7 cells. Zhu Z, Wilson AT, Gopalakrishna K, et al. J Med Virol. 2010 Feb;82(2):239-48.

Text Box: HIV/HCV Coinfection


Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Nunes D, Fleming C, Offner G,et al. Am J Gastroenterol. 2010 Feb 23. [Epub ahead of print]


Hepatitis C infection on immune recovery in HIV-positive patients on successful HAART: The role of genotype 3. Seminari E, Tinelli C, Ravasi G, et al. Curr HIV Res. 2010 Feb 18. [Epub ahead of print]


Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. Bedimo R, Westfall AO, Mugavero et al. HIV Med. 2010 Feb 16. [Epub ahead of print]


Hepatitis C and the risk of kidney disease and mortality in veterans with HIV.

Fischer MJ, Wyatt CM, Gordon K, et al. J Acquir Immune Defic Syndr. 2010 Feb 1;53(2):222-6.


Text Box: Complementary and Alternative Medicine


Complementary and alternative medicine use in chronic liver disease patients. Ferrucci LM, Bell BP, Dhotre KB, et al. J Clin Gastroenterol. 2010 Feb;44(2):e40-5.


Text Box: Epidemiology, Diagnostics, and Miscellaneous Works

Attribution of hepatitis C virus seroconversion risk in young injection drug users in 5 US cities. Hagan H, Pouget ER, Williams IT, et al. J Infect Dis. 2010 Feb 1;201(3):378-85.


Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with micro-somal triglyceride transfer protein (MTP). Mirandola S, Bowman D, Hussain MM, Alberti A. Nutr Metab (Lond). 2010 Feb 23;7(1):13. [Epub ahead of print]


Monitoring peripheral blood CD4+ adenosine triphosphate activity in recurrent hepatitis C and its correlation to fibrosis progression. Alkhouri N, Hanouneh IA, Lopez R, Zein NN. Liver Transpl. 2010 Feb;16(2):155-62.


Management of acute hepatitis C. Maheshwari A, Thuluvath PJ. Clin Liver Dis. 2010 Feb;14(1):169-76; x.